echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Antitumor Therapy > Gastrointest Endosc: The risk of Barrett's esobar developing into an esothy tube tumor!

    Gastrointest Endosc: The risk of Barrett's esobar developing into an esothy tube tumor!

    • Last Update: 2021-02-10
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    Barrett's esotherape (BE), the scaly end of the esotheria, produces a columnal superseed with cup cells, most commonly seen in patients with chronic gastroesoesopause reflow.
    Barrett's esophageal is the only definitive pre-cancer lesions of esophageal cancer.
    current understanding of the risk of tumor progression in Patients with Barrett esotrachea (BE-IND) carrying uncertain heterogeneous growth (IND) is derived from small retrospective and pathological registration studies.
    study is a multi-center queue study designed to determine tumor incidence in patients with BE-IND.
    study process included patients diagnosed with BE-IND from two academic centers who received endoscopic follow-up (FU) of up to 1 year or more if there was no evidence of heterogeneity in the past.
    1997-2017, 465 BE-IND patients were screened and 223 (48.0%) excluded.
    of the 242 patients included in the analysis, 184 (76.0%) did not see heterogeneity during follow-up.
    23 cases (9.5%) of patients with tumors (low-level heterogeneous growth (LGD) 20 cases, highly heterogenous growth (HGD) 2 cases, mucous endometrial cancer (IMC) 1 case); After 1.5 years (IQR 0.6-3.2 years), 35 (14.5%) new tumors (LGD 27, HGD 5, IMC 3).
    BE length and tumor occurrence all tumors and HGD/IMC incidence rates were 3.2 cases... Nebula Source: MedSci Original Copyright Notice: All text, images and audio and video materials on this website that state "Source: Mets Medicine" or "Source: MedSci Originals" are owned by Mets Medical and are not reproduced by any media, website or individual without authorization, and must be reproduced with the words "Source: Mets Medicine".
    all reprinted articles on this website are for the purpose of transmitting more information and clearly indicate the source and author, and media or individuals who do not wish to be reproduced may contact us and we will delete them immediately.
    reproduce content at the same time does not represent the position of this site.
    leave a message here
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.